Dynamic ctDNA Monitoring Guides Early Treatment Intensification in Locally Advanced Rectal Cancer Undergoing Neoadjuvant Chemotherapy

Dynamic ctDNA monitoring identifies patients with LARC at high risk for NCT failure as early as two cycles into treatment, which can form the basis for an adaptive trial design and eventual personalization of therapy selection.